Abstract:The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes approximately 3% of therapeutic drugs (n > 30; e.g. valproic acid, pilocarpine, tegafur, fadrozole, ifosfamide, cyclophosphamide, nicotine, tamoxifen, promazine, propofol, and cisapride), environmental toxicants (e.g. gasoline additives), and many procarcinogens such as nitrosamines and aflatoxin B(1). This enzyme also participates in the biotransformation of several endogenous compounds such as retinoid acids and steroids. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. Site-directed mutagenesis and homology modeling studies have identified a number of amino acids (e.g. F300, A301, S208, S369, and L370) that play a role in substrate recognition and binding. CYP2A6 shows a crystal structure with a compact, hydrophobic active site with Asn297 serving as one hydrogen bond donor and orienting substrates for regio-selective oxidation. CYP2A6 contains the second smallest active site cavity among the human CYPs with known structures. The regulation mechanism of CYP2A6 expression is not fully understood, but available data suggest that several nuclear receptors including constitutive androstane receptor, pregnane X receptor and glucocorticoid receptor are involved in its regulation. Pilocarpine and tranylcypromine are commonly used as selective competitive inhibitors of CYP2A6. Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6. Both in vitro and in vivo studies have demonstrated a wide (20- to >100-fold) interindividual variation in CYP2A6 expression and activity, which is due primarily to genetic polymorphisms in the CYP2A6 gene, but CYP2A6 activity is also modified by certain drugs and pathological and environmental factors. To date, more than 36 variant alleles (*1B through *37) of the CYP2A6 gene have been identified. There have been 278 SNPs found in the CYP2A6 upstream sequence, 8 introns and 9 exons in NCBI dbSNP. Polymorphism of CYP2A6 has been associated with smoking behavior, drug clearance and lung cancer risk. Further studies are warranted to explore the role of CYP2A6 in clinical practice, drug development and toxicology.

Cloning of CYP2J2 Gene and Identification of Functional Polymorphisms

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Identification And Functional Characterization Of New Potentially Defective Alleles Of Human Cyp2c19

CYP2J2*7 Single Nucleotide Polymorphism in a Chinese Population.

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance.

Cloning of a new human cytochrome P450 2A6 cDNA

Discovery of New Potentially Defective Alleles of Human Cyp2c9

Cytochrome P450 2j2: Distribution, Function, Regulation, Genetic Polymorphisms and Clinical Significance

Deep mutational scanning of CYP2C19 in human cells reveals a substrate specificity-abundance tradeoff

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro

Structural and Functional Insights into CYP2C8.3: A Genetic Polymorph of Cytochrome P450 2C8

Polymorphisms of Human Cytochrome P450 2c9 and the Functional Relevance

Identification And Functional Assessment Of A New Cyp2c9 Allelic Variant Cyp2c9(Star)59

Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants

Cloning of Human Cytochrome P450 2A6 Cdna and Its Expression in Mammalian Cells

Search for an Association Between the Human CYP1A2 Genotype and CYP1A2 Metabolic Phenotype.

The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant

An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62

Identification Of A Novel Variant Cyp2c9 Allele In Chinese

Massively parallel characterization of CYP2C9 variant enzyme activity and abundance